Media + Coverage
Eyes, mitochondria and a growing hub
9 January 2026
Base to Base Biotech podcast 41
Listen to podcast
In the News
Vandria announces positive phase 1 data for Alzheimer’s treatment
5 December 2025
PMLive
Read NewsVandria announces topline results from Phase I trial of VNA-318
3 December 2025
Clinical Trials Arena
Read NewsVandria moves Alzheimer’s candidate forward after Phase 1 signal
2 December 2025
Longevity Technology
Read ArticleSwiss biotech plots Series B raise to advance Alzheimer’s drug into Phase 2
2 December 2025
Endpoints News
Read ArticleVandria’s phase I data offer new mode of action in Alzheimer’s
2 December 2025
BioWorld
Read Article [Behind Paywall]Vandria reports VNA-318’s first-in-human data in Alzheimer’s
2 December 2025
Labiotech
Read ArticleVandria advances positive Phase I data and eyes 2026 series B
2 December 2025
The Pharma Letter
Read Article [Behind Paywall]Vandria reports positive phase 1 data for Alzheimer’s drug candidate
2 December 2025
PharmaTimes
Read NewsVandria seeks series B funding to advance Alzheimer’s candidate into Phase II
2 December 2025
FirstWord Pharma
Read NewsIs this mitochondria’s big moment?
9 October 2025
Longevity Technology
Read articleLausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
6 May 2025
Biotech TV
View videoAre mitochondrial therapeutics about to go mainstream?
21 March 2025
Beyond Biotech
Listen to podcastDistillery spotlight: new mitochondrial mechanisms from academia
12 March 2024
BioCentury
Read article [Behind Paywall]Vandria begins clinical trials for Alzheimer’s drug VNA-318
7 January 2025
GGBA
Read newsVandria announces topline results from Phase I trial of VNA-318
3 December 2025
Clinical Trials Arena
Read NewsVandria begins clinical trials for promising mitophagy inducer
18 December 2024
Longevity Technology
Read newsEuropean Biotech Targeting Anti-ageing
2 October 2024
Pharmatech
View articleVandria Raises Second Series A; Round Totals $30.7M
21 August 2024
FinSMEs
Read newsVandria closes Series A round at CHF28.3m
21 August 2024
European Biotechnology
Read newsVandria: renewing mitochondria to treat CNS, muscle and other diseases
28 March 2024
BioCentury
Read article [Behind Paywall]Vandria awarded €3.8M in prestigious Innosuisse and Eurostars grants
14 February 2024
BIONITY.COM
Read newsGrant will advance VNA-318 for Parkinson’s, age-related diseases
13 February 2024
Parkinson’s News Today
Read articleVandria awarded grants to advance mitophagy drug candidates
8 February 2024
BioWorld
Read news [Behind Paywall]Vandria launches to treat age-related diseases
5 January 2024
Chemical & Engineering News
Read newsVandria SA Raises CHF18m for Neurodegenerative Disease Treatment
17 December 2023
BioProcess Updates
Read newsVandria raises USD 20.6M and emerges from stealth
15 December 2023
Startup ticker.ch
Read newsVandria emerges from stealth with $20.6m and clinic-ready lead candidate
14 December 2023
Longevity Technology
Read news
